Literature DB >> 25202775

Prescription histories and dose strengths associated with overdose deaths.

Anne Hirsch, Scott K Proescholdbell, William Bronson, Nabarun Dasgupta.   

Abstract

OBJECTIVE: Misuse, abuse, and diversion of prescription drugs are large and growing public health problems that have resulted in an overdose epidemic. We investigated whether short-acting or extended-release opioids were more frequently prescribed to those who died of an overdose and whether there was a linear relationship between dose strength and associated overdose deaths.
METHODS: The study population was North Carolina residents in 2010. We conducted a retrospective, population-based, descriptive study of medication histories of overdose decedents using data from vital statistics, medical examiner records, and a prescription drug monitoring program.
RESULTS: Unintentional or undetermined drug overdoses were responsible for 892 deaths. Out of 191 deaths involving methadone, only two were patients in opioid treatment programs. Immediate-release oxycodone was involved in the greatest number of opioid-related deaths. Out of 221 oxycodone deaths, 134 (61%) of the decedents filled a prescription for oxycodone in the 60 days prior to death. The most common strength dispensed within 60 days to a decedent who died of an oxycodone overdose was 10 mg for immediate-release (72 prescriptions). Immediate-release oxycodone products (rho = 1.00, P < 0.01) and extended-release fentanyl products (rho = 1.00, P < 0.01) showed strong increasing linear trends between dose strength and proportion of prescriptions dispensed to decedents.
CONCLUSIONS: A significant proportion of overdose decedents had been prescribed the same type of drugs that contributed to their death, especially for decedents who died from overdoses involving oxycodone, hydrocodone, and alprazolam. Higher dose strengths for certain opioids had higher associated mortality, and certain immediate-release opioids may be considered for public health prevention efforts.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25202775     DOI: 10.1111/pme.12391

Source DB:  PubMed          Journal:  Pain Med        ISSN: 1526-2375            Impact factor:   3.750


  18 in total

1.  Nonclinical safety assessment of PF614: A novel TAAP prodrug of oxycodone for chronic pain indication.

Authors:  P S Joshi; N Sanakkayala; L Kirkpatrick; P S Terse
Journal:  Regul Toxicol Pharmacol       Date:  2019-07-27       Impact factor: 3.271

2.  Dental opioid prescribing and multiple opioid prescriptions among dental patients: Administrative data from the South Carolina prescription drug monitoring program.

Authors:  Jenna L McCauley; J Madison Hyer; V Ramesh Ramakrishnan; Renata Leite; Cathy L Melvin; Roger B Fillingim; Christie Frick; Kathleen T Brady
Journal:  J Am Dent Assoc       Date:  2016-04-05       Impact factor: 3.634

Review 3.  What we know, and don't know, about the impact of state policy and systems-level interventions on prescription drug overdose.

Authors:  Tamara M Haegerich; Leonard J Paulozzi; Brian J Manns; Christopher M Jones
Journal:  Drug Alcohol Depend       Date:  2014-10-14       Impact factor: 4.492

4.  The Contribution of Prescribed and Illicit Opioids to Fatal Overdoses in Massachusetts, 2013-2015.

Authors:  Alexander Y Walley; Dana Bernson; Marc R Larochelle; Traci C Green; Leonard Young; Thomas Land
Journal:  Public Health Rep       Date:  2019-10-02       Impact factor: 2.792

5.  Using medical examiner case narratives to improve opioid overdose surveillance.

Authors:  Emily Hurstak; Christopher Rowe; Caitlin Turner; Emily Behar; Rachel Cabugao; Nikolas P Lemos; Catherine Burke; Phillip Coffin
Journal:  Int J Drug Policy       Date:  2018-01-30

6.  Opioid prescribing and risk mitigation implementation in the management of acute pain: Results from The National Dental Practice-Based Research Network.

Authors:  Jenna L McCauley; Renata S Leite; Valeria V Gordan; Roger B Fillingim; Gregg H Gilbert; Cyril Meyerowitz; David Cochran; D Brad Rindal; Kathleen T Brady
Journal:  J Am Dent Assoc       Date:  2018-03-15       Impact factor: 3.634

7.  Effects of Acute and Repeated Administration of Oxycodone and Naloxone-Precipitated Withdrawal on Intracranial Self-Stimulation in Rats.

Authors:  Jason M Wiebelhaus; D Matthew Walentiny; Patrick M Beardsley
Journal:  J Pharmacol Exp Ther       Date:  2015-10-21       Impact factor: 4.030

8.  Nonrandomized Intervention Study of Naloxone Coprescription for Primary Care Patients Receiving Long-Term Opioid Therapy for Pain.

Authors:  Phillip O Coffin; Emily Behar; Christopher Rowe; Glenn-Milo Santos; Diana Coffa; Matthew Bald; Eric Vittinghoff
Journal:  Ann Intern Med       Date:  2016-06-28       Impact factor: 25.391

9.  Comparative Rates of Mortality and Serious Adverse Effects Among Commonly Prescribed Opioid Analgesics.

Authors:  David L Murphy; Jacob A Lebin; Stevan G Severtson; Heather A Olsen; Nabarun Dasgupta; Richard C Dart
Journal:  Drug Saf       Date:  2018-08       Impact factor: 5.606

10.  Prevalence and incidence of prescription opioid analgesic use in Australia.

Authors:  Samanta Lalic; Jenni Ilomäki; J Simon Bell; Maarit Jaana Korhonen; Natasa Gisev
Journal:  Br J Clin Pharmacol       Date:  2018-11-16       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.